Akuttherapie der Schizophrenie

T. Wobrock; P. Falkai; F.-G. Pajonk

doi:10.1055/s-2004-818454

Fortschritte der Neurologie · Psychiatrie, Inhaltsverzeichnis

Fortschr Neurol Psychiatr 2004; 72(12): 705-726
DOI: 10.1055/s-2004-818454

Fort- und Weiterbildung

Akuttherapie der Schizophrenie

Acute Treatment of SchizophreniaT. Wobrock¹ , P. Falkai¹ , F.-G. Pajonk¹

¹Universitäts-Nervenklinik - Psychiatrie und Psychotherapie - Universitätskliniken des Saarlandes, Homburg/Saar (Direktor: Prof. Dr. med. P. Falkai)

Abstract

Volltext

Referenzen

Literatur

1 Addonizio G, Susman V, Roth S. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry. 1986; 143 1587-1590
2 Allison D B, Mentore J L, Heo M. et al . Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156 1686-1696
3 American Psychiatric Association . Practice guideline for the treatment of patients with schizophrenia. Second edition. Am J Psychiatry. 2004; Supplement 1-114
4 Azorin J M, Spiegel R, Remington G, Vanelle J M, Péré J J, Giguere M, Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001; 158 1305-1313
5 Barak Y, Shamir E, Zemishlani H, Mirecki I, Toren P, Weizman R. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26 1199-1202
6 Barnas C, Quiner S, Tauscher J, Hilger E, Willeit M, Kufferle B, Asenbaum S, Brucke T, Rao M L, Kasper S. In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmacology (Berl). 2001; 157 236-242
7 Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L. et al . Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997; 15 335-340
8 Bench C J, Lammertsma A A, Grasby P M, Dolan R J, Warrington S J, Boyce M, Gunn K P, Brannick L Y, Frackowiak R S. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology. 1996; 124 141-147
9 Benkert O, Hippius H . Kompendium der Psychiatrischen Pharmakotherapie, 4. Auflage. Berlin, Heidelberg, New York: Springer-Verlag 2003
10 Bieniek S A, Ownby R L, Penalver A, Dominguez R A. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy. 1998; 18 57-62
11 Casey D E, Daniel D G, Wassef A A, Tracy L A, Wozniak P, Sommerville K W. Replyeffect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003; 28 2052-2053
12 Copolov D L, Link C G, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med. 2000; 30 95-105
13 Currier G W, Simpson G M. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001; 62 153-157
14 Daniel D G, Potkin S G, Reeves K R, Swift R H, Harrigan E P. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl). 2001; 155 128-134
15 Davis J M, Chen N, Glick I D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003; 60 553-564
16 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (Hrsg) .Praxisleitlinien in Psychiatrie und Psychotherapie (Band 1). Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff 1998
17 Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991; 41 369-371
18 Drury V, Birchwood M, Cochrane R. Cognitive therapy and recovery from acute psychosis: a controlled trial. Br J Psychiatry. 2000; 177 8-14
19 Falloon I RH. Family interventions for mental disorders: efficacy and effectiveness. World Psychiatry. 2003; 2 20-28
20 Fenton M K, Coutinho E SF, Campbell C. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses. (Cochrane-Review). In: The Cochrane Library, Issue 2, 2003. Oxford, Update Software
21 Foster S, Kessel J, Berman M E, Simpson G M. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol. 1997; 12 175-179
22 Freudenreich O, Goff D C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002; 106 323-330
23 Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res. 2002; 53 145-159
24 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000; 321 1371-1376
25 Gefvert O, Bergstrom M, Laangstrom B, Lundberg T, Lindstrom I, Yates R A. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuitation of quetiapine in patients with schizophrenia. Psychopharmacology. 1998; 135 119-126
26 Glick I D, Lemmens P, Vester-Blokland E. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. Int Clin Psychopharmacol. 2001; 16 265-274
27 Gunasekara N S, Spencer C M, Keating G M. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2002; 62 1217-1251
28 Henderson D, Nasrallah R, Goff D. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry. 1998; 59 585-588
29 Hogarty G E, Anderson C M, Reiss D J, Kornblinth S J, Greenwald P, Javan C D, Manonia M J,. EPICS research group . Family psychoeducation, social skills training and maintenance chemotherapy in the aftercare treatment of schizophrenia. Arch Gen Psychiatry. 1986; 43 633-642
30 Hori M, Suzuki T, Sasaki M, Shiraishi H, Koizumi J. Convulsive seizures in schizophrenic patients induced by zotepine administration. Jpn J Psychiatry Neurol. 1992; 46 161-167
31 Johns C, Thompson J. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophr Bull. 1995; 21 607-619
32 Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45 789-796
33 Kane J M, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol. 1988; 8 52-56
34 Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R. High levels of dopamine D₂ receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996; 153 948-950
35 Kapur S, Zipursky R B, Remington G. Clinical and theoretical implication of 5-HT₂ and D₂ receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999; 156 286-293
36 Kapur S, Zipursky R B, Jones C, Remington G, Houle S. Relationship between dopamine D₂ occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157 514-520
37 Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry. 1998; 172 413-419
38 Kopala L C, Good K P, Honer W G. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low dose risperidone. J Clin Psychopharmacol. 1997; 17 308-313
39 Koro C E, Fedder D O, L'Italien G J, Weiss S, Magder L S, Kreyenbuhl J, Revicki D, Buchanan R W. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002; 59 1021-1026
40 Krausz M, Moritz S, Lambert M, Naber D. Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia. Int J Psychopharmacol. 2000; 2 77-81
41 Lehmann A F, Steinwachs D M,. PORT Co-investigators . Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998; 24 1-10
42 Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol. 2000; 23 284-286
43 Lewis S, Tarrier N, Haddock G, Bentall R, Kinderman P, Kingdon D, Siddle R, Drake R, Everitt J, Leadley K, Benn A, Grazebrook K, Haley C, Akhtar S, Davies L, Palmer S, Faragher B, Dunn G. Randomised controlled trial of cognitive-behavioral therapy in early schizophrenia: acute-phase outcomes. Br J Psychiatry (Suppl.). 2002; 43 S91-S97
44 Lieberman J A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry. 1996; 57 (Suppl. 11) 68-71
45 Lieberman J A, Koreen A, Chakos M, Sheitman B, Woerner M, Alvir J M, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996; 57 (Suppl. 9) 5-9
46 Lieberman J A, Tollefson G, Tohen M, Green A I, Gur R E, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer R M. HGDH Study Group . Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry . 2003; 160 1396-1404
47 Lindenmayer J P, Volavka J, Lieberman J, Sheitman B, Citrome L, Chakos M, Czobor P, Parker B, Iskander A. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J Clin Psychopharmacol.. 2001; 21 448-453
48 Loebel A D, Lieberman J A, Alvir J M, Mayerhoff D I, Geisler S H, Szymanski S R. Duration of psychosis and outcome in first episode schizophrenia. Am J Psychiatry. 1992; 149 1183-1188
49 Martinot J L, Paillere-Martinot M L, Poirier M F, Dao-Castellana M H, Loch C, Maziere B. In vivo characteristics of dopamine D₂ receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl). 1996; 124 154-158
50 McGorry P D, Edwards J, Mihalopoulos C. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull. 1996; 22 305-322
51 Möller H J, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbation of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology. 1997; 132 396-401
52 Mullen J, Jibson M D, Sweitzer D. for the QUEST Study Group . A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001; 23 1839-1854
53 National Institute for Clinical Excellence .Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. NICE Technology Appraisal Guidance - No. 43. 2002
54 Nordstrom A L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedval G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995; 152 1444-1449
55 Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone based on PET-measured D₂ and 5-HT_2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999; 156 869-875
56 Nyberg S, Olsson H, Nilsson U, Maehlum E, Halldin C, Farde L. Low striatal and extra-striatal D₂ receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl). 2002; 162 37-41
57 Pajonk F G, Raedler T J, Schreiner A, Wiedemann K. Effectiveness of risperidone in higly agitated schizophrenic patients. European Neuropsychopharmacol. 2002; 12 (Suppl 3) S276
58 Robinson D G, Woerner M G, Alvir J M, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman J A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999; 156 544-549
59 Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia. (Cochrane-Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
60 Sanger T M, Lieberman J A, Tohen M, Grundy S, Beasley C, Tollefson G D. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry. 1999; 156 79-87
61 Scholer N R. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull. 1991; 17 311-324
62 Tandon R, Jibson M D. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003; 28 9-26
63 Thayran P, Adams C E. Electroconvulsive therapy for schizophrenia. (Cochrane-Review). In: The Cochrane Library, Issue 4, 2002. Chichester, UK: John Wiley & Sons, Ltd.
64 Tollefson G D, Birkett M A, Kiesler G M, Wood A J,. Lilly Resistant Schizophrenia Study Group . Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001; 49 52-63
65 Bruggen J van, Tijssen J, Dingemans P, Gersons B, Linszen D. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol. 2003; 18 341-346
66 Putten T van, Marder S R, Mintz J. A controlled dose comparison of haloperidol of newly admitted schizophrenic patients. Arch Gen Psychiatry. 1990; 47 754-758
67 Volz H P, Pajonk F G. Akuttherapie schizophrener Psychosen. Stuttgart: Thieme-Verlag 2003: S.33-36
68 Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomised pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2000; 24 911-922
69 Wetzel H, Bardeleben U von, Holsboer F, Benkert O. Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppelblind-kontrollierte Wirksamkeitsprüfung. Fortschr Neurol Psychiat. 1991; 59 (Suppl. 1) 23-29
70 Wiedemann G, Klingberg S. Psychotherapie produktiver Symptomatik bei Patienten mit schizophrener Psychose. Nervenarzt. 2003; 74 76-84
71 Wright P, Birkett M, David S R, Meehan K, Ferchland I, Alaka K J. et al . Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001; 158 1149-1151

Dr. med. Thomas Wobrock

Universitäts-Nervenklinik - Psychiatrie und Psychotherapie Universitätskliniken des Saarlandes

66421 Homburg/Saar

eMail: thomas.wobrock@uniklinik-saarland.de